Peyton C. High

This study shows that combining LGR5 and MET-targeting antibody-drug conjugates with different payloads improves efficacy and delays tumor relapse in colorectal cancer models.

EGFR:LGR5 bispecific antibody-drug conjugates show strong antitumor effects and outperform other ADCs in colorectal cancer models.

This study shows cetuximab increases LGR5 expression and improves the efficacy of LGR5-targeting ADCs in colorectal cancer models.

This study develops and tests EREG-targeting ADCs showing efficacy in both RAS mutant and wildtype CRC, with high potency and safety in preclinical models.